Researchers identified a 3-biomarker immunoassay, measuring NNMT, LCP1, and NM23A, that successfully distinguishes healthy patients from those with renal cell carcinoma (RCC). If their results can be validated, physicians would have an unprecedented tool for the early detection and subsequent treatment of this silent and deadly disease.
Researchers at the University of Cincinnati College of Medicine, Ohio State University, and Johns Hopkins have identified several biomarkers of early kidney damage in patients suffering from lupus. Various combinations of the markers, including neutrophil gelatinase-associated lipocalin (NGAL) and monocyte chemotactic protein 1 (MCP-1), along with more traditional kidney markers, were able to accurately predict [...]
Several biomarkers, including neutrophil gelatinase-associated lipocalin (NGAL) and interleukin-18, were found to be useful in predicting the progression and severity of acute kidney injury after cardiac surgery. Biomarkers such as these which help detect disease at earlier stages are useful to improve the care of patients undergoing these procedures. View Article »